Skin changes have several possible causes. A local mark and a spreading rash need different assessment, but location alone cannot diagnose the cause. A rash, hives or itching may be part of an allergic reaction. The numbers below come from the current US prescribing information, June 2026 [1]. For what Ozempic is, see our Ozempic guide.
Reactions where you inject were reported by 0.2% of people in Ozempic's trials
In placebo-controlled trials, injection site reactions (e.g., injection-site discomfort, erythema) were reported in 0.2% of OZEMPIC-treated patients.[1]
Erythema means redness. That's about 1 person in 500. The label's examples are discomfort and redness, and it does not provide a bruising-specific rate. Do not interpret 0.2% as the incidence of all bruises. If bruising is new, frequent, large or worsening, ask your pharmacist or prescriber to assess it and review injection technique. They can show you in person, which a page can't.
The Ozempic label doesn't list easy bruising or bleeding as a side effect
Bruising that shows up away from the injection spot, or bruising more easily in general, doesn't appear anywhere in Ozempic's prescribing information [1]. That absence does not identify the cause of a bruise or prove that a drug-related effect is impossible.
If you notice new bruising, tell your prescriber and list everything you take, including supplements. The Medication Guide asks for that full list anyway, because Ozempic may affect the way some medicines work.
Rash and hives are in Ozempic's reports after approval, at an unknown rate
The label's postmarketing section lists four allergic reactions reported with semaglutide: anaphylaxis, angioedema (deep swelling, often of the face or throat), rash and urticaria (hives) [1]. It adds an important caveat:
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.[1]
So the label can't say how common a rash is, only that it has been reported. Ozempic's label gives no rate for itching; its Medication Guide names "severe rash or itching" as a sign of a serious allergic reaction. The Wegovy label, for the same molecule, does include itching (pruritus) among its injection-site reactions [2]. Wegovy's pediatric trial also reported rash and hives in 3% each, against none on placebo.
Serious allergic reactions, including anaphylaxis and angioedema, have been reported with Ozempic
This is the skin-related warning that matters most. The label tells prescribers to stop Ozempic if a hypersensitivity reaction occurs, treat it, and monitor until it resolves. It also says not to use Ozempic after a serious allergic reaction to semaglutide or an ingredient in the product [1].
| What you notice | What the label connects it to | What to do |
|---|---|---|
| Redness or soreness where you injected | Injection-site reactions including discomfort and redness: 0.2% in trials; no bruising-specific rate | Ask your clinician about new, persistent or worsening changes; seek urgent help for serious allergic signs |
| Redness or itching at the spot that spreads or worsens | Not specifically described | Call your prescriber |
| A rash or hives elsewhere on your body | Postmarketing hypersensitivity reports | Call your prescriber promptly |
| A severe rash or severe itching | Serious allergic reaction (Medication Guide) | Stop Ozempic and get medical help right away |
| Swelling of the face, lips, tongue or throat | Angioedema or anaphylaxis | Stop Ozempic and get emergency help |
| Trouble breathing or swallowing, fainting, dizziness, very rapid heartbeat | Serious allergic reaction | Stop Ozempic and get emergency help |
Ozempic prescribing information §5.8 and §6.2 and Medication Guide, DailyMed version 20, June 2026.
If you've had anaphylaxis or angioedema with another GLP-1 drug, tell your prescriber before starting. The label says it is unknown whether such people are more likely to react to Ozempic, and it asks for caution [1].
Different labels describe different trials and populations
Each label comes from different trials, so these rows aren't a head-to-head comparison. They describe observations from different doses and populations, so the percentages cannot establish that one drug is intrinsically safer or more likely to cause a reaction.
| Drug (label) | Injection-site reactions | Rash, hives, itching | Serious allergic reactions |
|---|---|---|---|
| Ozempic (June 2026) | 0.2% | Rash and hives in postmarketing reports | Anaphylaxis, angioedema: label warning |
| Wegovy injection (adult rates; pediatric rash separately) | 1.4% vs 1% placebo; includes itching, redness, swelling | Rash 3% and hives 3% vs 0% in the pediatric trial | Anaphylaxis, angioedema: label warning |
| Zepbound (adult weight-management trials) | 6% (5 mg), 8% (10 mg), 8% (15 mg) vs 2%; includes injection-site bruising | Hypersensitivity 5% vs 3%, mostly rash and itching | Anaphylaxis, angioedema: label warning |
| Mounjaro (adult diabetes trials) | 3.2% vs 0.4% | Hypersensitivity 3.2% vs 1.7%, sometimes severe (hives, eczema) | Anaphylaxis, angioedema: label warning |
Wegovy, Zepbound and Mounjaro prescribing information on DailyMed (versions 19, 40 and 40). Different trials and populations; not a head-to-head comparison.
Zepbound’s pooled injection-site term explicitly includes bruising, but the combined rate is not a bruising-specific rate [3]. Mounjaro's label reports hypersensitivity reactions "sometimes severe (e.g., urticaria and eczema)" [4]. For the full picture on those drugs, see tirzepatide side effects, and for Wegovy, Wegovy side effects.
Joint pain isn't on the Ozempic label
Joint pain, joint swelling and arthralgia don't appear in Ozempic's prescribing information [1]. That doesn't rule out a link for any one person, but the label gives nothing to go on. If you have new joint pain or swelling, tell your prescriber. Swelling of the face, lips or throat is a different matter and belongs in the emergency row above.
Hair loss is listed in Ozempic's reports after approval
Alopecia, the medical term for hair loss, appears under skin reactions in Ozempic's postmarketing list, again at an unknown rate [1]. Wegovy’s adult 2.4 mg injection trials report 3.3% versus 1% on placebo and describe an association with weight reduction [2]. For Ozempic's other side effects and its warnings, see is Ozempic safe?; for its stomach effects, see Ozempic's stomach side effects; and for facial changes, see "Ozempic face".